CD59 and cancer: Repressing the terminal lysis capacity of the complement system through the involvement of the inhibiting RCA protein CD59 is characteristic of cancer resistance and of the action of infectious pathogens, which tend to hijack the complement system regulators to defend from its aggression [10,11,12,13,14].